Pregnant women significantly more likely to be admitted to ICU, receive invasive ventilation, ECMO, die
TUESDAY, Nov. 3, 2020 (HealthDay News) — Pregnant women with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have increased risks for severe COVID-19-associated illness, according to research published in the Nov. 2 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Laura D. Zambrano, Ph.D., from the CDC COVID-19 Response Team, and colleagues provide updated information about symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2.
The CDC received reports for 1,300,938 women aged 15 to 44 years with laboratory results indicative of acute infection with SARS-CoV-2. The researchers found that for 35.5 percent of women with laboratory-confirmed infection, data on pregnancy status were available, and 88.7 percent were symptomatic. Among symptomatic women, 5.7 percent were reported to be pregnant. Pregnant women were significantly more likely to be admitted to an intensive care unit, receive invasive ventilation, receive extracorporeal membrane oxygenation, and die compared with nonpregnant women after adjustment for age, race, and underlying medical conditions (adjusted risk ratios, 3.0, 2.9, 2.4, and 1.7, respectively). Disparities in risk by subgroup were highlighted on stratification by age and race/ethnicity.
“Understanding the risk posed by SARS-CoV-2 infection in pregnant women can inform clinical practice, risk communication, and medical countermeasure allocation,” the authors write. “Pregnant women should be informed of their risk for severe COVID-19-associated illness and the warning signs of severe COVID-19.”
Pregnancy Complications Rare for Women Receiving CAR T-Cell Therapy
Higher Parental Vitamin B12 Tied to Lower Prevalence of Birth Defects
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders
Dose-Dependent Link Seen for Clomiphene Citrate, Adverse Perinatal Outcomes
Recommendations Updated for Management of Anemia in CKD
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus
Therapies Compared for Newly Diagnosed Multiple Sclerosis
Initial Rx Length Tied to Long-Term Use of Z-Drugs